Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

From today, the new STENOCARE THC/CBD medical cannabis oil product is available for sale in Denmark

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO On February 26, 2024, STENOCARE A/S (“Stenocare”) announced, that it had received approval to supply a new THC/CBD medical cannabis oil product under the Danish Pilot Programme. Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different

SemiQon’s quantum processor testing and measurement facilities at the VTT MIKES premises up and running

SemiQon is the first company to operate within the laboratory premises of the Finnish National Metrology Institute VTT MIKES. The new facilities support SemiQon’s commitment to advancing world-class measurement expertise and infrastructure for building scalable quantum hardware.ESPOO, Finland (April 18th, 2024) SemiQon's measurement and testing facilities within the premises of the National Metrology Institute VTT MIKES are now finalized and fully operational. SemiQon will be the first deep-tech company benefiting from one of the best metrological research infrastructures in the world for

Genexis joins 25GS-PON MSA Group

Genexis is now one of the 64 current members and industry leaders to have joined the initiative.25GS-PON Multi-Source Agreement (MSA) Group aims to promote and accelerate the development of 25 Gigabit Symmetric Passive Optical Network (25GS-PON) technology and define its specifications. Many of the world’s top operators and vendors see 25GS-PON as a crucial technology. It provides a cost-effective and timely network upgrade path that can meet the needs of the mobile 5G era and large-scale enterprises, where symmetrical connections become increasingly important. “We are delighted to join

NAVA – a gamechanger for neonatal care in Slovakia

When using Getinge’s patented Neurally Adjusted Ventilatory Assist (NAVA) with diaphragm monitoring (Edi) for the first time in 2021, it soon became clear to the neonatal team in the F.D. Roosevelt University Hospital in Banska Bystrica, Slovakia, that the solution would become a gamechanger for their treatment of premature babies. The first case for the F.D. Roosevelt University Hospital in Banska Bystrica using NAVA involved a tiny premature girl, born in the 22[nd] week, who developed severe Bronchopulmonary Dysplasia (BPD). “She was in such poor condition that we couldn’t

Invitation to presentation of MilDef´s first quarter report 2024, on April 26

MilDef, a leading supplier of tactical IT, software solutions and services, will publish its first quarter report 2024 on April 26, at 08:00 am CET.A conference (on Teams) for investors, analysts and media will be held at 10.00-10.45 CET that same day. The report will be presented by Daniel Ljunggren, CEO and CFO Viveca Johnsson.  The presentation will be held in English and is concluded with a Q&A session, moderated by Olof Engvall, Head of Investor Relations. Presentation material will be made available on www.mildef.com the same morning. Notification is not required for

Invitation to the presentation of Ratos Interim report January-March 2024

The Interim report January-March 2024 will be released on Monday 29 April at 07.00 CEST.At 09.00 CEST will Jonas Wiström, President and CEO, and Jonas Ågrup, CFO, present the report.The presentation can be followed on Youtube via the following link; https://youtube.com/live/m1pxBSsaufo?feature=shareThe live presentation will be recorded and is available afterwards via the same link.Participants who wish to ask questions live are asked to pre-register, please send an e-mail to helena.jansson@ratos.com in advance for a personal invitation.The presentation and report will be available

Sandvik wins order in Mongolia for electric rotary drill rigs

Sandvik has received an order from Mongolyn Alt MAK LLC to supply electric rotary drill rigs for use at the Tsagaan Suvarga Project in Mongolia. The order is valued at approximately SEK 170 million and was booked in the first quarter 2024. The order includes five cable-electric DR410iE drills, with deliveries scheduled to begin in the second quarter 2024 and concluded by the fourth quarter of 2025. Tsagaan Suvarga ranks as the third-largest copper and molybdenum reserve in Mongolia. “We are very pleased to be selected to supply our advanced electric rotary drill rigs to Mongolyn Alt

Invitation to UPM’s webcast and conference call on Q1 2024 interim report

(UPM, Helsinki, 18 April 2024 at 10:00 EEST) – UPM will publish its Q1 2024 interim report on Thursday, 25 April 2024 at 09:30–10:00 EEST. After publishing, the report will be available on the company website at www.upm.com . A webcast and a conference call for analysts and investors begins at 13:15 EEST. The interim report will be presented in English by President and CEO Massimo Reynaudo and CFO Tapio Korpeinen. Participants can view the webcast online through this link . Those who wish to ask questions from

Correction (date) Presentation of Probi’s Q1 Report 2024

Probi’s report for the first quarter 2024 will be published on Tuesday, 23 April at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q1-report-2024 

OrderYOYO A/S publishes Strong Q1 performance showing 33% ARR growth and EBITDA significantly higher than previous guidance showing 15% EBITDA margin. Guidance for 2024 raised

Company Announcement No. 72 - 2024 OrderYOYO A/SInside Information Copenhagen, April 18, 2024 Highlights Business continues to perform strongly and above guidance. Highly focused strategy solving digital challenges for our Restaurant Partners continues to reap rewards to the benefit of both our Restaurant Partners and OrderYOYO Q1 2024 results show a significant higher growth in ARR and Net Revenue than prior guidance. March 2024 ARR is thus DKK 300m corresponding to a growth of 33% compared to March 2023. Q1 2024 Net Revenue is DKK 73m corresponding to a growth of 35%

Diamyd Medical announces final outcome in the company’s rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. On April 16, 2024, Diamyd Medical AB (publ) (“

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation’s stock exchange release on April 18, 2024, at 9:45 a.m. EESTMetso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On April 16, 2024, BlackRock's holding in Metso’s shares exceeded the 5 percent threshold and amounted to 41,639,734 shares or 5.02 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 1,154,425 shares, which corresponds to 0.13 percent of the total amount of Metso’s shares. On

Wyld Networks receive first satellite IoT-data from the IoT-company Net Reply in Italy

Virtual satellite operator Wyld Networks have received its first satellite IoT-data from Italy. Moving forward this data is revenue generating. Net Reply are part of the Reply SPA conglomerate focused on network innovation within infrastructure, based in Italy, the UK, and the US with revenues of over Euro 2 billion in 2023.Revenue in the Italian Internet of Things (IoT) market is expected to show an annual growth rate (CAGR 2024-2028) of 9.34%, resulting in a market volume of US$32.73bn by 2028. However, lack of coverage for sectors such as utilities, energy and agriculture is holding back

Interim report first quarter 2024

First Quarter (Jan–March 2024) · Net sales amounted to TSEK 159,001 (121,296), which is an increase of 31.1 % compared to the same period last year. · The gross margin amounted to 51.9 % (56.4). · Operating profit before depreciation (EBITDA) amounted to TSEK 45,722 (28,459), which corresponds to an operating margin before depreciation of 28.8 % (23.5). · Operating profit (EBIT) amounted to TSEK 29,524 (16,100), which corresponds to an operating margin of 18.6 % (13.3). · Earnings per share before dilution amounted to SEK 2.03 (1.16).(Comparative figures in parentheses

Wärtsilä cargo handling and fuel gas supply systems selected for three new Very Large Ethane Gas Carriers

Wärtsilä Corporation, Press release, 18 April 2024 at 9.30 AM EESTWärtsilä Gas Solutions, part of technology group Wärtsilä, will supply cargo handling and fuel supply systems  for three new large sized ethane gas carrier (VLEC) vessels. The ships are being built at the HD Hyundai Heavy Industries (HHI) yard in Korea for owner Purus. The order, which was booked by Wärtsilä in Q1 2024, further strengthens Wärtsilä’s market-leading position in this sector. In line with the Purus’ emphasis on achieving net zero carbon emissions for its

Invitation for presentation of Pricer’s interim report for the first quarter 2024

Pricer AB will present its interim report for the first quarter 2024 in a webcast on April 25 at 13.00 CET.According to the financial calendar, Pricer will publish the report for the first quarter 2024 on Thursday, April 25 at approximately 8.30 am CET. Pricer hereby invites to a presentation of the report on the same day. Magnus Larsson, President and CEO, and Claes Wenthzel, acting CFO, will present the report and answer questions. Date: April 25, 2024 Time: 13.00 CET Link to the webcast: https://ir.financialhearings.com/pricer-ab-q1-report-2024 

Inwido’s science-based targets approved

Inwido's science-based targets have been approved by the Science Based Targets initiative. By setting science-based targets, work towards further reductions in greenhouse gas emissions (GHG) is ensured in line with the Paris Agreement's objective of limiting global warming to 1.5°C. Inwido commits to reach net-zero GHG emissions across the value chain by 2050."We are proud that our climate targets have been validated by SBTi. It is an important milestone that shows our ambition to be a leader in sustainability for windows and doors in Europe. We have clear processes and plans in place to

Invitation to conference call, April 25 at 14:00 (CEST)

Studsvik AB presents its Interim Report for the First Quarter 2024 and hereby invites media and analysts to a conference call held in English on Thursday, April 25 at 14:00 (CEST).Studsvik’s Interim Report for the First Quarter 2024 will be distributed at approximately 12:00 am (CEST), April 25. As of this time, the report will also be available at www.studsvik.com. The call will be held in English, starting 14:00 (CEST). If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. Studsvik Q1 Report 2024 (

Toivo Group Oyj - Managers' Transactions - Samuli Niemela

Toivo Group Oyj - Managers' Transactions  - Samuli Niemela – April 18 9:30 a.m. ____________________________________________ Person subject to the notification requirement Name: Samuli Niemelä Position: Closely associated person  (1):Person Discharging Managerial Responsibilities In Issuer Name: Samuli Niemelä Position: Chief Financial Officer Issuer: Toivo Group Oyj LEI: 743700N31WYJDNPT8M98 Notification type: INITIAL NOTIFICATION Reference number: 58295/6/6 7 / 8 ____________________________________________ Transaction date: 2024-04-12 Venue:

Toivo Group Oyj - Managers' Transactions – Urho Myllymäki

Toivo Group Oyj - Managers' Transactions – Urho Myllymäki April 18[th] 2024 9:30 ____________________________________________ Person subject to the notification requirement Name: Urho Myllymäki Position: Other senior manager  Issuer: Toivo Group Oyj LEI: 743700N31WYJDNPT8M98 Notification type: INITIAL NOTIFICATION Reference number: 58291/7/8 ____________________________________________ Transaction date: 2024-04-12 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000496716 Nature of transaction: DISPOSAL Transaction

Correction (date) Presentation of Probi’s Q1 Report 2024

Probi’s report for the first quarter 2024 will be published on Tuesday, 23 April at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q1-report-2024 

Aptahem plans to perform a Proof-of-Concept Phase 2 study in patients with its lead candidate Apta-1

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announces that the company has decided to revise its clinical development strategy by performing a Proof-of-Concept (PoC) study in patients as the next step in the clinical development of the drug candidate Apta-1. The aim with the planned study is to evaluate effect of Apta-1 in patients with acute and serious inflammatory diseases. The final study design is now under evaluation.After analyzing the results from the performed Phase 1a study, including the

Observe Medical transfers Nordic distribution to Vingmed

Oslo, April 18, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces transfer of its Nordic distribution operations to Vingmed, following a strategic review. The Company assessed the relevance of the business, originally established as a platform for testing and launching its branded products. Given the expansion of our global distribution capabilities, which now fulfill our initial testing and pre-launch needs, the business is becoming less crucial to our core operations. Consequently, we have decided to seek more suitable ownership of the Nordic operations going

Nexam Chemical Holding AB (publ) Interim Report 1 January – 31 March 2024

Increased EBITDA and positive cash flowFirst quarter at a glance Significant events during the quarter: · Sales increased by 2% compared to the corresponding quarter in 2023 and the gross margin increased from 42% to 45%. Sequentially, revenue increased by 5% compared to the fourth quarter of 2023. · EBITDA increased to SEK 2,212,000, which is a sequential increase of 42% compared to the fourth quarter of 2023. · The cost saving program has run according to plan and has had full effect at the end of the quarter. · Performance Masterbatch's sales decreased by 9% compared to

There are no items matching the current filter
There are no more items matching the current filter
Back to top